

Richard L Wahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5892088/publications.pdf>

Version: 2024-02-01

310
papers

23,815
citations

8181

76
h-index

8630

146
g-index

326
all docs

326
docs citations

326
times ranked

18601
citing authors

#	ARTICLE	IF	CITATIONS
1	From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. Journal of Nuclear Medicine, 2009, 50, 122S-150S.	5.0	3,047
2	Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants. Radiographics, 1999, 19, 61-77.	3.3	757
3	¹³¹ I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. New England Journal of Medicine, 2005, 352, 441-449.	27.0	697
4	Metastases from Non-Small Cell Lung Cancer: Mediastinal Staging in the 1990s—Meta-analytic Comparison Of PET and CT. Radiology, 1999, 213, 530-536.	7.3	613
5	Dynamic Imaging of Allogeneic Mesenchymal Stem Cells Trafficking to Myocardial Infarction. Circulation, 2005, 112, 1451-1461.	1.6	561
6	Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2001, 19, 3918-3928.	1.6	555
7	Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody. New England Journal of Medicine, 1993, 329, 459-465.	27.0	531
8	Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study. Cancer, 1993, 72, 2979-2985.	4.1	521
9	Radioimmunotherapy with iodine 1311 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 2000, 96, 1259-1266.	1.4	465
10	Metrology Standards for Quantitative Imaging Biomarkers. Radiology, 2015, 277, 813-825.	7.3	347
11	Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2000, 18, 1316-1323.	1.6	337
12	Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group. Journal of Clinical Oncology, 2004, 22, 277-285.	1.6	314
13	Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology, 2016, 280, 576-584.	7.3	311
14	Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. Journal of Nuclear Medicine, 2003, 44, 170-6.	5.0	289
15	Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. Statistical Methods in Medical Research, 2015, 24, 27-67.	1.5	272
16	Normal FDG Distribution Patterns in the Head and Neck: PET/CT Evaluation. Radiology, 2005, 234, 879-885.	7.3	254
17	Noninvasive Quantification and Optimization of Acute Cell Retention by In Vivo Positron Emission Tomography After Intramyocardial Cardiac-Derived Stem Cell Delivery. Journal of the American College of Cardiology, 2009, 54, 1619-1626.	2.8	245
18	Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15172-15177.	7.1	244

#	ARTICLE	IF	CITATIONS
19	Brown Adipose Reporting Criteria in Imaging Studies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans. <i>Cell Metabolism</i> , 2016, 24, 210-222.	16.2	233
20	Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 7565-7573.	1.6	226
21	Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction. <i>Radiology</i> , 1999, 213, 521-525.	7.3	222
22	Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 603-606.	6.4	216
23	Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1797-803.	5.0	215
24	Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1238-1243.	6.4	210
25	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸ F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428.	5.0	209
26	Fluorodeoxyglucose Uptake in the Aortic Wall at PET/CT: Possible Finding for Active Atherosclerosis. <i>Radiology</i> , 2003, 229, 831-837.	7.3	207
27	¹⁸ F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. <i>Cancer</i> , 1991, 67, 1544-1550.	4.1	200
28	Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. <i>Gynecologic Oncology</i> , 2003, 90, 519-528.	1.4	189
29	"USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1267-70.	5.0	189
30	Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1041-1047.	5.0	186
31	Detection of unexpected additional primary malignancies with PET/CT. <i>Journal of Nuclear Medicine</i> , 2005, 46, 752-7.	5.0	174
32	Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. <i>Physics in Medicine and Biology</i> , 2013, 58, 7391-7418.	3.0	172
33	Ectopic Expression of the Sodium-Iodide Symporter Enables Imaging of Transplanted Cardiac Stem Cells In Vivo by Single-Photon Emission Computed Tomography or Positron Emission Tomography. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1652-1660.	2.8	166
34	CT Hounsfield Units of Brown Adipose Tissue Increase with Activation: Preclinical and Clinical Studies. <i>Journal of Nuclear Medicine</i> , 2010, 51, 246-250.	5.0	161
35	Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 240-3.	5.0	160
36	Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria) Interreader Reliability, Accuracy, and Survival Outcomes. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1411-1416.	5.0	156

#	ARTICLE	IF	CITATIONS
37	Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements. <i>Seminars in Nuclear Medicine</i> , 2003, 33, 228-237.	4.6	149
38	Dynamic whole-body PET imaging: principles, potentials and applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 501-518.	6.4	145
39	Imaging of Pelvic Malignancies with In-Line FDG PET—CT: Case Examples and Common Pitfalls of FDG PET. <i>Radiographics</i> , 2005, 25, 1031-1043.	3.3	143
40	The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7792-7798.	7.0	142
41	Hyperosmolar Sexual Lubricant Causes Epithelial Damage in the Distal Colon: Potential Implication for HIV Transmission. <i>Journal of Infectious Diseases</i> , 2007, 195, 703-710.	4.0	135
42	Initial experience with FDG-PET/CT in the evaluation of breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 254-262.	6.4	133
43	PET-CT: accuracy of PET and CT spatial registration of lung lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 721-726.	6.4	132
44	Direct Comparison of FDG PET and CT Findings in Patients with Lymphoma: Initial Experience. <i>Radiology</i> , 2005, 237, 1038-1045.	7.3	130
45	Exposure to strong static magnetic field slows the growth of human cancer cells in vitro. <i>Bioelectromagnetics</i> , 1996, 17, 358-363.	1.6	129
46	Expression of hexokinase II and Glut-1 in untreated human breast cancer. <i>Nuclear Medicine and Biology</i> , 2002, 29, 443-453.	0.6	129
47	¹⁸ F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1655-1665.	5.0	129
48	Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 615-620.	2.1	126
49	Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1008-1016.	5.0	123
50	Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic Decisions. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 308-340.	4.6	118
51	Germ Cell Tumor: Differentiation of Viable Tumor, Mature Teratoma, and Necrotic Tissue with FDG PET and Kinetic Modeling. <i>Radiology</i> , 1999, 211, 249-256.	7.3	112
52	Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1189-93.	5.0	112
53	Indium-111—Capromab Pendetide Radioimmunoscinigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1715-1721.	1.6	108
54	CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT Examination. <i>Radiology</i> , 2005, 237, 627-634.	7.3	107

#	ARTICLE	IF	CITATIONS
55	Effects of Nonionic Intravenous Contrast Agents at PET/CT Imaging: Phantom and Canine Studies. <i>Radiology</i> , 2003, 227, 817-824.	7.3	106
56	Quantitative Imaging in Cancer Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 284-290.	7.0	106
57	Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67 Ga-citrate, and 125 I-HSA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 333-341.	6.4	103
58	Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. <i>Gynecologic Oncology</i> , 2005, 99, 294-300.	1.4	100
59	PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1137-43.	5.0	97
60	Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey. <i>Journal of Nuclear Medicine</i> , 2011, 52, 311-317.	5.0	96
61	Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography using 2-Deoxy-2-[18F]Fluoro-D-Glucose. <i>Molecular Imaging and Biology</i> , 2002, 4, 171-178.	2.6	93
62	Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab. <i>Journal of Clinical Oncology</i> , 2005, 23, 7985-7993.	1.6	93
63	Summary of the UPICT Protocol for ¹⁸ F-FDG PET/CT Imaging in Oncology Clinical Trials. <i>Journal of Nuclear Medicine</i> , 2015, 56, 955-961.	5.0	93
64	Clinical use of positron emission tomography in the management of cutaneous melanoma. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 242-253.	4.6	86
65	FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 274-280.	6.4	85
66	Initial experience with oral contrast in PET/CT: phantom and clinical studies. <i>Journal of Nuclear Medicine</i> , 2003, 44, 412-6.	5.0	85
67	Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation. <i>Physics in Medicine and Biology</i> , 2013, 58, 7419-7445.	3.0	84
68	Promise and pitfalls of quantitative imaging in oncology clinical trials. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1301-1312.	1.8	83
69	Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1481-1484.	5.0	83
70	Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1767-1776.	5.0	81
71	Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 200-206.	2.1	81
72	The Added Diagnostic Value of Liquid Gastric Emptying Compared with Solid Emptying Alone. <i>Journal of Nuclear Medicine</i> , 2009, 50, 726-731.	5.0	81

#	ARTICLE	IF	CITATIONS
73	¹²⁴ I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1844-1847.	5.0	80
74	PET-CT in Recurrent Ovarian Cancer: Initial Observations. <i>Radiographics</i> , 2004, 24, 209-223.	3.3	79
75	FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2014, 39, 225-231.	1.3	79
76	Bone marrow cell trafficking following intravenous administration. <i>British Journal of Haematology</i> , 1999, 107, 895-902.	2.5	78
77	Current status of PET in breast cancer imaging, staging, and therapy. <i>Seminars in Roentgenology</i> , 2001, 36, 250-260.	0.6	78
78	Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET. <i>Physics in Medicine and Biology</i> , 2015, 60, 8643-8673.	3.0	78
79	Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 961-969.	1.7	77
80	Absolute myocardial flow quantification with ⁸² Rb PET/CT: comparison of different software packages and methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 126-135.	6.4	77
81	Imaging of Renal Cancer Using Positron Emission Tomography with 2-Deoxy-2-(¹⁸ F)-Fluoro-D-Glucose: Pilot Animal and Human Studies. <i>Journal of Urology</i> , 1991, 146, 1470-1474.	0.4	73
82	Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 597-602.	6.4	72
83	Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. <i>Medical Physics</i> , 2008, 35, 1123-1134.	3.0	70
84	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 539-546.	0.8	70
85	Myocardial substrate and route of administration determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 443-450.	2.1	69
86	Prediction of the Need for Surgical Intervention in Obstructive Crohn's Disease by ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1751-1759.	5.0	67
87	¹⁸ F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 8-17.	5.0	66
88	Assessment of Interobserver Reproducibility in Quantitative ¹⁸ F-FDG PET and CT Measurements of Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1760-1769.	5.0	65
89	The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. <i>Seminars in Oncology</i> , 2003, 30, 31-38.	2.2	65
90	Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 242-248.	2.0	64

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Positron Emission Tomography Using F-18-Fluorodeoxyglucose in Patients with Cervical Cancer Undergoing Radiotherapy. <i>Gynecologic Oncology</i> , 2002, 84, 289-295.	1.4	61
92	Effect of Nicotine and Ephedrine on the Accumulation of 18F-FDG in Brown Adipose Tissue. <i>Journal of Nuclear Medicine</i> , 2007, 48, 981-986.	5.0	61
93	TBCRC 008: Early Change in ¹⁸ F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	5.0	61
94	FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 2008, 20, 206-219.	2.4	60
95	Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 39-45.	6.4	59
96	The Promise and Pitfalls of Positron Emission Tomography and Single-Photon Emission Computed Tomography Molecular Imaging-Guided Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2011, 21, 88-100.	2.2	57
97	Study of the Impact of Tissue Density Heterogeneities on 3-Dimensional Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo Methods. <i>Journal of Nuclear Medicine</i> , 2013, 54, 236-243.	5.0	57
98	The Relationship between Patients' Serum Glucose Levels and Metabolically Active Brown Adipose Tissue Detected by PET/CT. <i>Molecular Imaging and Biology</i> , 2011, 13, 1278-1283.	2.6	56
99	Hyaluronic acid-human blood hydrogels for stem cell transplantation. <i>Biomaterials</i> , 2012, 33, 8026-8033.	11.4	56
100	Uptake of 2-Deoxy, 2-(18F) Fluoro-D-Glucose in Bladder Cancer: Animal Localization and Initial Patient Positron Emission Tomography. <i>Journal of Urology</i> , 1991, 145, 279-283.	0.4	55
101	Relationship of Delayed Enhancement by Magnetic Resonance to Myocardial Perfusion by Positron Emission Tomography in Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 210-217.	2.6	54
102	Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1985-94.	5.0	53
103	Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1274-80.	5.0	53
104	PET/CT: artifacts caused by bowel motion. <i>Nuclear Medicine Communications</i> , 2004, 25, 221-225.	1.1	52
105	Comparison of Uptake of Multiple Clinical Radiotracers into Brown Adipose Tissue Under Cold-Stimulated and Nonstimulated Conditions. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1715-1723.	5.0	52
106	Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 41-47.	6.4	52
107	Quantitative Assessment of Myocardial Blood Flow-Clinical and Research Applications. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 274-293.	4.6	52
108	Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. <i>American Journal of Roentgenology</i> , 2015, 204, 1093-1099.	2.2	52

#	ARTICLE	IF	CITATIONS
109	Preoperative Positron Emission Tomography to Evaluate Potentially Resectable Hepatic Colorectal Metastases. <i>Archives of Surgery</i> , 2006, 141, 1220.	2.2	50
110	Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. <i>Cancer Research</i> , 2003, 63, 6252-7.	0.9	50
111	A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1256-1262.	0.8	49
112	The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. <i>Radiology</i> , 2020, 294, 647-657.	7.3	49
113	Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning—Monte Carlo Simulation Studies. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 521-530.	8.9	48
114	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 550-562.	6.4	48
115	Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 457-64.	5.0	48
116	FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT. <i>Molecular Imaging and Biology</i> , 1998, 1, 123-129.	0.3	47
117	Sacral Fractures: A Potential Pitfall of FDG Positron Emission Tomography. <i>American Journal of Roentgenology</i> , 2003, 181, 1239-1243.	2.2	46
118	Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. <i>Medical Physics</i> , 2009, 36, 612-619.	3.0	46
119	PET/CT Assessment of Symptomatic Individuals with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 407-414.	5.0	46
120	Diagnosis and Differentiation of Bronchioloalveolar Carcinoma from Adenocarcinoma with Bronchioloalveolar Components with Metabolic and Anatomic Characteristics Using PET/CT. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1585-1592.	5.0	45
121	Follow-up or Surveillance ¹⁸F-FDG PET/CT and Survival Outcome in Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1062-1068.	5.0	45
122	Semi-quantitative ventilation/perfusion scintigraphy and single-photon emission tomography for evaluation of lung volume reduction surgery candidates: description and prediction of clinical outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 734-742.	6.4	44
123	Prognostic Value of FDG PET Metabolic Tumor Volume in Human Papillomavirus—Positive Stage III and IV Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Roentgenology</i> , 2014, 203, 897-903.	2.2	44
124	Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. <i>Journal of Nuclear Medicine</i> , 2006, 47, 603-8.	5.0	44
125	Regional 2-[18F]fluoro-2-deoxy-d-glucose uptake varies in normal lung. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 517-523.	2.1	43
126	Cardiac PET/CT Misregistration Causes Significant Changes in Estimated Myocardial Blood Flow. <i>Journal of Nuclear Medicine</i> , 2013, 54, 50-54.	5.0	43

#	ARTICLE	IF	CITATIONS
127	Noninvasive methods for the assessment of brown adipose tissue in humans. <i>Journal of Physiology</i> , 2018, 596, 363-378.	2.9	43
128	Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development. <i>Journal of Nuclear Medicine</i> , 2022, 63, 500-510.	5.0	43
129	Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. <i>Journal of Nuclear Medicine</i> , 2006, 47, 950-6.	5.0	43
130	Head and Neck Cancer: Detection of Recurrence with Three-dimensional Principal Components Analysis at Dynamic FDG PET. <i>Radiology</i> , 1999, 212, 285-290.	7.3	42
131	Visualization of Brown Adipose Tissue with ^{99m} Tc-Methoxyisobutylisonitrile on SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2008, 49, 752-756.	5.0	42
132	¹⁸ F-FDG PET/CT Radiomic Analysis with Machine Learning for Identifying Bone Marrow Involvement in the Patients with Suspected Relapsed Acute Leukemia. <i>Theranostics</i> , 2019, 9, 4730-4739.	10.0	41
133	Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists. <i>Journal of Nuclear Medicine</i> , 2011, 52, 830-838.	5.0	40
134	18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1923-1931.	5.0	39
135	Addition of ¹⁸ F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2039-2045.	5.0	39
136	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 845-852.	1.2	39
137	Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 596-604.	6.4	38
138	The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. <i>Journal of Neuro-Oncology</i> , 2017, 132, 513-519.	2.9	38
139	Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of U.S. Medical Oncologists and Hematologists. <i>Journal of Nuclear Medicine</i> , 2010, 51, 987-994.	5.0	36
140	Tumor Dosimetry and Response for ¹⁵³ Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 215-224.	5.0	36
141	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	1.6	36
142	Reproducibility of Tumor Blood Flow Quantification with ¹⁵ O-Water PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1620-1627.	5.0	35
143	Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. <i>Translational Research</i> , 2012, 159, 51-57.	5.0	34
144	Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1977-84.	5.0	34

#	ARTICLE	IF	CITATIONS
145	Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 40-45.	6.4	33
146	Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. <i>Investigational New Drugs</i> , 2009, 27, 120-123.	2.6	33
147	Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 32-37.	2.5	32
148	Comparison of quantitative ^{90}Y SPECT and non- ^{90}Y PET imaging in post-therapy radioembolization of liver cancer. <i>Medical Physics</i> , 2016, 43, 5779-5790.	3.0	32
149	Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 23S-35S.	5.0	32
150	Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. <i>Cancer</i> , 2002, 94, 1258-1263.	4.1	31
151	Comprehensive Radionuclide Esophagogastrointestinal Transit Study: Methodology, Reference Values, and Initial Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2015, 56, 721-727.	5.0	31
152	Hyaluronic acid-serum hydrogels rapidly restore metabolism of encapsulated stem cells and promote engraftment. <i>Biomaterials</i> , 2015, 73, 1-11.	11.4	30
153	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1219-1235.	0.8	30
154	^{18}F -FDG PET/CT and Lung Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. <i>Journal of Nuclear Medicine</i> , 2015, 56, 204-208.	5.0	29
155	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , 2018, 25, 1405-1414.	2.5	29
156	Simultaneous measurement of noise and spatial resolution in PET phantom images. <i>Physics in Medicine and Biology</i> , 2010, 55, 1069-1081.	3.0	28
157	Dynamic Multi-Bed FDG PET imaging: Feasibility and optimization. , 2011, , .		28
158	Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with ^{89}Zr in Human Lymphoma Xenografts. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1219-1224.	5.0	28
159	Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. <i>Journal of Nuclear Medicine</i> , 2004, 45 Suppl 1, 82S-95S.	5.0	28
160	Applications of PET in Liver Imaging. <i>Radiologic Clinics of North America</i> , 2005, 43, 849-860.	1.8	27
161	Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 379-381.	1.3	27
162	FDG-PET Lymphoma Demonstration Project Invitational Workshop. <i>Academic Radiology</i> , 2007, 14, 330-339.	2.5	27

#	ARTICLE	IF	CITATIONS
163	Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with ⁹⁰ Y-Ibritumomab Tiuxetan or ¹³¹ I-Tositumomab. Journal of Nuclear Medicine, 2010, 51, 1878-1884.	5.0	27
164	Repeatability of ¹⁸ F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. Journal of Nuclear Medicine, 2017, 58, 393-398.	5.0	27
165	PERCIST in Perspective. Nuclear Medicine and Molecular Imaging, 2018, 52, 1-4.	1.0	27
166	Therapeutic potential of ⁹⁰ Y- and ¹³¹ I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. Journal of Nuclear Medicine, 2007, 48, 150-7.	5.0	27
167	Evaluation of ion-implanted-silicon detectors for use in intraoperative positron-sensitive probes. Medical Physics, 1996, 23, 1889-1895.	3.0	26
168	A Practical, Automated Quality Assurance Method for Measuring Spatial Resolution in PET. Journal of Nuclear Medicine, 2009, 50, 1307-1314.	5.0	26
169	Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning in patient studies. Medical Physics, 2009, 36, 1595-1601.	3.0	26
170	Comparison of FDG-PET/CT and CT for Delineation of Lumpectomy Cavity for Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2008, 71, 595-602.	0.8	25
171	In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab. Journal of Nuclear Medicine, 2008, 49, 674-678.	5.0	25
172	Response to Early Treatment Evaluated with ¹⁸ F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor. Journal of Nuclear Medicine, 2016, 57, 735-740.	5.0	25
173	Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. Annals of Nuclear Medicine, 2017, 31, 109-124.	2.2	24
174	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. JACC: Cardiovascular Imaging, 2018, 11, 320-332.	5.3	24
175	Tumor Response Assessment Is More Robust With Sequential CT Scanning Than External Caliper Measurements. Academic Radiology, 2005, 12, 776-781.	2.5	23
176	Effect of Patient Arm Motion in Whole-Body PET/CT. Journal of Nuclear Medicine, 2011, 52, 1891-1897.	5.0	23
177	Measurement Repeatability of ¹⁸ F-FDG PET/CT Versus ¹⁸ F-FDG PET/MRI in Solid Tumors of the Pelvis. Journal of Nuclear Medicine, 2019, 60, 1080-1086.	5.0	23
178	A Multisite Study of a Breast Density Deep Learning Model for Full-Field Digital Mammography and Synthetic Mammography. Radiology: Artificial Intelligence, 2021, 3, e200015.	5.8	23
179	How Reproducible Is Bioluminescent Imaging of Tumor Cell Growth? Single Time Point versus the Dynamic Measurement Approach. Molecular Imaging, 2007, 6, 7290.2007.00031.	1.4	22
180	Comparison and Effectiveness of Regadenoson Versus Dipyridamole on Stress Electrocardiographic Changes During Positron Emission Tomography Evaluation of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 1033-1039.	1.6	22

#	ARTICLE	IF	CITATIONS
181	Liver Standardized Uptake Value Corrected for Lean Body Mass at FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e17-e22.	1.3	22
182	Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry and ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1243-1248.	5.0	22
183	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
184	Advantages of Hybrid SPECT/CT vs SPECT Alone. <i>The Open Medical Imaging Journal</i> , 2008, 2, 67-79.	0.8	22
185	Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. <i>Journal of Nuclear Medicine</i> , 2007, 48 Suppl 1, 19S-27S.	5.0	22
186	Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with ¹⁸ F-Fluorodeoxyglucose in Humans. <i>Cell Metabolism</i> , 2019, 30, 212-224.e4.	16.2	21
187	Tositumomab and (¹³¹ I) therapy in non-Hodgkin's lymphoma. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 128S-40S.	5.0	21
188	FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. <i>Current Opinion in Oncology</i> , 2004, 16, 100-105.	2.4	20
189	Scalene muscle uptake: a potential pitfall in head and neck PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 89-94.	6.4	20
190	Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 1013-1022.	2.4	20
191	Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1535-1542.	5.0	20
192	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2300-2309.	6.4	20
193	Intratumoral microdistribution of [¹³¹ I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 1997, 24, 657-663.	0.6	19
194	PET Scanning and Measuring the Impact of Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 119-134.	2.0	19
195	Imaging Uterine Cervical Cancer with FDG-PET/CT: Direct Comparison with PET. <i>Molecular Imaging and Biology</i> , 2009, 11, 229-235.	2.6	19
196	Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma. <i>Nuclear Medicine Communications</i> , 2011, 32, 1046-1051.	1.1	19
197	Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data. <i>EJNMMI Research</i> , 2014, 4, 67.	2.5	19
198	Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1014-1016.	5.0	19

#	ARTICLE	IF	CITATIONS
199	Repeatability of brown adipose tissue measurements on FDG PET/CT following a simple cooling procedure for BAT activation. PLoS ONE, 2019, 14, e0214765.	2.5	19
200	Quantitative Fit Tested N95 Respirator-Alternatives Generated With CT Imaging and 3D Printing: A Response to Potential Shortages During the COVID-19 Pandemic. Academic Radiology, 2021, 28, 158-165.	2.5	19
201	At Last, ¹⁸ F-FDG for Inflammation and Infection!. Journal of Nuclear Medicine, 2021, 62, 1048-1049.	5.0	19
202	Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. Journal of Nuclear Medicine, 2003, 44, 1541-3; author reply 1543.	5.0	19
203	Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. Journal of Nuclear Medicine, 2021, 62, 60S-72S.	5.0	19
204	Performance assessment of a NaI(Tl) gamma counter for PET applications with methods for improved quantitative accuracy and greater standardization. EJNMMI Physics, 2015, 2, .	2.7	18
205	Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms. Journal of Nuclear Cardiology, 2016, 23, 1304-1314.	2.1	18
206	A Snapshot of Radiology Training During the Early COVID-19 Pandemic. Current Problems in Diagnostic Radiology, 2021, 50, 607-613.	1.4	18
207	How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Molecular Imaging, 2007, 6, 315-22.	1.4	18
208	Radiosynthesis of [¹¹ C]paclitaxel. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 471-477.	1.0	17
209	Synthesis and in vivo evaluation of (S)-6-(4-fluorophenoxy)-3-((1-[¹¹ C]methylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one, a potential PET tracer for growth hormone secretagogue receptor (GHSR). Bioorganic and Medicinal Chemistry, 2011, 19, 2368-2372.	3.0	17
210	Assessment of Tumorcidal Efficacy and Response to Treatment with ¹⁸ F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. Journal of Nuclear Medicine, 2011, 52, 225-230.	5.0	17
211	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. Journal of Clinical Oncology, 2016, 34, 3680-3685.	1.6	17
212	Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications. PLoS ONE, 2009, 4, e6200.	2.5	17
213	F-18 FDG PET/CT in Acute Respiratory Distress Syndrome: A Case Report. Clinical Nuclear Medicine, 2004, 29, 786-788.	1.3	16
214	Letter to Cancer Center Directors: Progress in Quantitative Imaging As a Means to Predict and/or Measure Tumor Response in Cancer Therapy Trials. Journal of Clinical Oncology, 2014, 32, 2115-2116.	1.6	16
215	Respiratory-gated PET/CT versus delayed images for the quantitative evaluation of lower pulmonary and hepatic lesions. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 277-282.	1.8	16
216	Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?. European Heart Journal Cardiovascular Imaging, 2016, 17, 293-300.	1.2	16

#	ARTICLE	IF	CITATIONS
217	A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-III A resectable NSCLC. EJNMMI Research, 2017, 7, 8.	2.5	16
218	Synthesis and Biodistribution of [11C]Adenosine 5-AMP. Molecular Imaging and Biology, 2005, 7, 203-208.	2.6	15
219	The effect of specimen processing on radiolabeled monoclonal antibody biodistribution. European Journal of Nuclear Medicine and Molecular Imaging, 1984, 9, 382-4.	2.1	14
220	Simplifying volumes of interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole organ VOIs. Medical Physics, 2017, 44, 1707-1717.	3.0	14
221	Quantitative PET/CT in clinical practice. Nuclear Medicine Communications, 2018, 39, 154-160.	1.1	14
222	Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2021, 62, 6-14.	5.0	13
223	Anatomomolecular Imaging with 2-Deoxy-2-[18F]Fluoro-D-Glucose: Bench to Outpatient Center. Molecular Imaging and Biology, 2003, 5, 49-56.	2.6	12
224	Arterial Wall Dosimetry for Non-Hodgkin Lymphoma Patients Treated with Radioimmunotherapy. Journal of Nuclear Medicine, 2010, 51, 368-375.	5.0	12
225	Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Molecular Imaging and Biology, 2017, 19, 429-436.	2.6	12
226	Preclinical PERCIST and 25% of SUV _{max} Threshold: Precision Imaging of Response to Therapy in Co-clinical ¹⁸ F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. Journal of Nuclear Medicine, 2020, 61, 842-849.	5.0	12
227	Repeatability of ¹⁸ F-FDG PET Radiomic Features in Cervical Cancer. Journal of Nuclear Medicine, 2021, 62, 707-715.	5.0	12
228	Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.. Blood, 2009, 114, 3759-3759.	1.4	12
229	Experimental radioimmunotherapy. A brief overview. Cancer, 1994, 73, 989-992.	4.1	11
230	Extramedullary Hematopoiesis on F-18 FDG PET/CT in a Patient With Metastatic Colon Carcinoma. Clinical Nuclear Medicine, 2007, 32, 878-880.	1.3	11
231	Characterization of a Perirectal Artifact in ¹⁸ F-FDG PET/CT. Journal of Nuclear Medicine, 2010, 51, 1501-1506.	5.0	11
232	Quantitative FDG PET/CT in the community: Experience from interpretation of outside oncologic PET/CT exams in referred cancer patients. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 183-188.	1.8	11
233	Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. Journal of Nuclear Medicine, 2017, 58, 1429-1434.	5.0	11
234	Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. EJNMMI Research, 2018, 8, 52.	2.5	11

#	ARTICLE	IF	CITATIONS
235	Human Radiation Dosimetry for Orally and Intravenously Administered ¹⁸ F-FDG. Journal of Nuclear Medicine, 2020, 61, 613-619.	5.0	11
236	¹⁸ F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2337-2345.	6.4	10
237	Two-Time-Point FDG PET/CT: Liver SUL _{mean} Repeatability. American Journal of Roentgenology, 2015, 204, 402-407.	2.2	10
238	Theranostics: The Role of Quantitative Nuclear Medicine Imaging. Seminars in Radiation Oncology, 2021, 31, 28-36.	2.2	10
239	Improved ²²³ Ra Therapy with Combination Epithelial Sodium Channel Blockade. Journal of Nuclear Medicine, 2021, 62, 1751-1758.	5.0	10
240	High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts. Cancer Immunology, Immunotherapy, 1987, 24, 221-4.	4.2	9
241	Magnetically-enhanced radionuclide therapy (MERiT): In vitro evaluation. International Journal of Radiation Oncology Biology Physics, 1997, 37, 1201-1206.	0.8	9
242	PET/CT findings in gastric cancer: potential advantages and current limitations. Imaging in Medicine, 2012, 4, 241-250.	0.0	9
243	Strengths and Weaknesses of a Planar Whole-Body Method of ¹⁵³ Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 369-379.	1.0	9
244	Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (¹¹¹ In)/Yttrium 90 (⁹⁰ Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers, 2021, 13, 2828.	3.7	8
245	Studies on the metabolic fate of ¹¹¹ In-labeled antibodies. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1989, 16, 839-845.	0.3	7
246	Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecologic Oncology, 2005, 98, 510-512.	1.4	7
247	Synthesis of 2-[¹⁸ F]fluoroadenosine (2-[¹⁸ F]FAD) as potential radiotracer for studying malignancies by PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 811-815.	1.0	7
248	Overcorrection of iodinated contrast attenuation in SPECT-CT: Phantom studies. Medical Physics, 2010, 37, 4897-4901.	3.0	7
249	The role of ¹⁸ F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma. Journal of Radiation Oncology, 2013, 2, 341-352.	0.7	7
250	Optimal definition of biological tumor volume using positron emission tomography in an animal model. EJNMMI Research, 2015, 5, 58.	2.5	7
251	Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹ In-Pentetreotide Quantitative SPECT/CT. Journal of Nuclear Medicine, 2015, 56, 985-988.	5.0	7
252	Phase I/II Dose-Escalation Study of Tositumomab and Iodine I ¹³¹ Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety. Blood, 2008, 112, 3059-3059.	1.4	7

#	ARTICLE	IF	CITATIONS
253	An Exocrine Pancreatic Stress Test with ¹¹ C-Acetate PET and Secretin Stimulation. Journal of Nuclear Medicine, 2014, 55, 1128-1131.	5.0	6
254	Quo Vadis: PET and Single-Photon Molecular Breast Imaging. Journal of Nuclear Medicine, 2016, 57, 3S-8S.	5.0	6
255	DNA Repair After Exposure to Ionizing Radiation Is Not Error-Free. Journal of Nuclear Medicine, 2018, 59, 348-348.	5.0	6
256	Repeatability of Radiomic Features of Brown Adipose Tissue. Journal of Nuclear Medicine, 2021, 62, 700-706.	5.0	6
257	Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of ⁶⁸ Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy. Molecular Imaging and Biology, 2021, 23, 766-774.	2.6	6
258	Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 432-435.	2.1	5
259	Measuring the "Unmeasurable". Academic Radiology, 2010, 17, 1175-1185.	2.5	5
260	Quantitative whole-body parametric PET imaging incorporating a generalized Patlak model. , 2013, , .		5
261	Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma. EJNMMI Research, 2016, 6, 42.	2.5	5
262	Overview of the First NRG Oncology "National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2021, 62, 1133-1139.	5.0	5
263	Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century. Journal of Nuclear Medicine, 2021, 62, 34S-43S.	5.0	5
264	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Journal of Nuclear Medicine, 2022, 63, 1836-1843.	5.0	5
265	A Positron-Emitting Internal Marker for Identification of Normal Tissue by Positron Emission Tomography: Phantom Studies and Validation in Patients. Molecular Imaging and Biology, 2003, 5, 79-85.	2.6	4
266	Enhanced whole-body PET parametric imaging using hybrid regression and thresholding driven by kinetic correlations. , 2012, , .		4
267	Quantitation of cancer treatment response by 2-[¹⁸ F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST. EJNMMI Research, 2021, 11, 15.	2.5	4
268	Brown Adipose Tissue: A Protective Mechanism Against "Preprediabetes". Journal of Nuclear Medicine, 2022, 63, 1433-1440.	5.0	4
269	Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice. Journal of Nuclear Medicine, 2021, 62, 1S-2S.	5.0	4
270	A Projection-Domain Low-Count Quantitative SPECT Method for ^É -Particle-Emitting Radiopharmaceutical Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences, 2023, 7, 62-74.	3.7	4

#	ARTICLE	IF	CITATIONS
271	Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: Theory of application. <i>Medical Physics</i> , 1995, 22, 1285-1292.	3.0	3
272	Positron Emission Tomography (PET): an Update on Applications in Breast Cancer. <i>Breast Disease</i> , 1998, 10, 165-175.	0.8	3
273	Longitudinal Myocardial Blood Flow Gradient and CAD Detection. <i>Current Cardiology Reports</i> , 2015, 17, 550.	2.9	3
274	Bioluminescent Tumor Signal Is Mouse Strain and Pelt Color Dependent: Experience in a Disseminated Lymphoma Model. <i>Molecular Imaging and Biology</i> , 2021, 23, 697-702.	2.6	3
275	Detection of additional primary neoplasms on 18F-Fluciclovine PET/CT in patients with primary prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262647.	5.0	3
276	Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study. , 1993, 72, 2979.		3
277	Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10509-10509.	1.6	3
278	Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/paraganglioma (Pheo).. <i>Journal of Clinical Oncology</i> , 2012, 30, e13592-e13592.	1.6	3
279	Increased genital uptake of 99mTc red blood cells: A potential cause of false-positive studies for gastrointestinal bleeding. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1984, 9, 245-246.	2.1	2
280	Diagnosis of exercise-induced left bundle branch block at rest by scintigraphic phase analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1986, 11, 434-7.	2.1	2
281	The Roles of Fluorodeoxyglucose-PET/Computed Tomography in Ovarian Cancer: Diagnosis, Assessing Response, and Detecting Recurrence. <i>PET Clinics</i> , 2010, 5, 447-461.	3.0	2
282	Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1780-1781.	5.0	2
283	Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks. <i>Journal of Nuclear Medicine</i> , 2019, 60, 437-438.	5.0	2
284	The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 471-483.	4.6	2
285	Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy.. <i>Blood</i> , 2007, 110, 1894-1894.	1.4	2
286	Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2105-TPS2105.	1.6	2
287	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. <i>Tomography</i> , 2020, 6, 60-64.	1.8	2
288	Observational Retrospective Study of Altered Biodistribution of Tositumomab and ¹³¹ I-Tositumomab. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1800-1803.	5.0	1

#	ARTICLE	IF	CITATIONS
289	Reply to E. HindiÃ© et al. Journal of Clinical Oncology, 2019, 37, 2092-2093.	1.6	1
290	Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.. Journal of Clinical Oncology, 2014, 32, 189-189.	1.6	1
291	Diagnosis of Stage IV Melanoma. , 2019, , 1-47.		1
292	Business Models for Academic Medical Center Cyclotron Operations. Journal of the American College of Radiology, 2005, 2, 526-533.	1.8	0
293	Clinical Significance of Iodine-123 Metaiodobenzylguanidine Cardiac Imaging. Journal of the American College of Cardiology, 2009, 54, 575-576.	2.8	0
294	Surveillance of Cancer Patients with Imaging: Self-Evident or Evidence-Based?. Journal of Nuclear Medicine, 2013, 54, 1513-1515.	5.0	0
295	Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, â€œBexxarâ€). Medical Radiology, 2014, , 505-525.	0.1	0
296	Case Report. Medicine (United States), 2015, 94, e1820.	1.0	0
297	Imaging Melanoma. , 2019, , 557-581.		0
298	PET Diagnosis and Response Monitoring in Oncology. , 2021, , 1049-1076.		0
299	Lymphomas. , 2013, , 153-187.		0
300	Imaging Metabolic and Molecular Functions in Brain Tumors with Positron Emission Tomography (PET). , 2014, , 129-142.		0
301	Functional Imaging. Medical Radiology, 2014, , 159-166.	0.1	0
302	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2016, , 1-42.		0
303	Radionuclide Therapy of Lymphomas. , 2016, , 1-15.		0
304	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2017, , 353-393.		0
305	Radionuclide Therapy of Lymphomas. , 2017, , 1141-1155.		0
306	Imaging Melanoma. , 2018, , 1-25.		0

#	ARTICLE	IF	CITATIONS
307	Diagnosis of Stage IV Melanoma. , 2020, , 997-1043.		0
308	PET and PET/CT Imaging in Breast Cancer. , 2006, , 197-215.		0
309	Individualizing cancer therapies using "anatomolecular" imaging. Journal of Nuclear Medicine, 2008, 49, 65N-68N.	5.0	0
310	Use of combined PET/CT imaging in evaluation of the solitary pulmonary nodule: Principles, techniques, and pitfalls. , 0, , 24-43.		0